Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization.
Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community.
Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.
《Regenerative Medicine》是一本由FUTURE MEDICINE LTD出版商出版的專業醫學期刊，該刊創刊于2006年，刊期Bimonthly，該刊已被國際權威數據庫SCIE收錄。在中科院最新升級版分區表中，該刊分區信息為大類學科：工程技術 4區，小類學科：細胞與組織工程 4區；工程：生物醫學 4區；在JCR（Journal Citation Reports）分區等級為Q3。該刊發文范圍涵蓋細胞與組織工程等領域，旨在及時、準確、全面地報道國內外細胞與組織工程工作者在該領域取得的最新研究成果、工作進展及學術動態、技術革新等，促進學術交流，鼓勵學術創新。2021年影響因子為3.21，平均審稿速度較慢,6-12周。
| 大類學科 | 分區 | 小類學科 | 分區 | Top期刊 | 綜述期刊 |
| 工程技術 | 4區 | CELL & TISSUE ENGINEERING 細胞與組織工程 ENGINEERING, BIOMEDICAL 工程：生物醫學 | 4區 4區 | 否 | 否 |
| JCR分區等級 | JCR所屬學科 | 分區 | 影響因子 |
| Q3 | ENGINEERING, BIOMEDICAL | Q3 | 3.21 |
| CELL & TISSUE ENGINEERING | Q4 |
| 影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
| 3.21 | 53 | 21.03% | 56.34% | 未開放 | 較慢,6-12周 |
投稿咨詢
課題、SCI/EI/SSCI怎么寫？